Mylan Inc. MYL today
announced that its subsidiary Mylan Pharmaceuticals Inc. has received final
approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated
New Drug Application (ANDA) for Phenytoin Chewable Tablets USP, 50 mg. This
product is the generic version of Pfizer's Dilantin® Chewable Tablets, which
are indicated for the control of generalized tonic-clonic (grand mal) and
complex partial (psychomotor, temporal lobe) seizures and prevention and
treatment of seizures occurring during or following neurosurgery. Phenytoin
serum level determinations may be necessary for optimal dosage adjustments.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in